Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 8, 2024
Abstract
PET/CT
targeting
prostate-specific
membrane
antigen
(PSMA)
is
commonly
used
in
patients
with
prostate
cancer.
PSMA
has
been
found
other
solid
tumours,
including
primary
brain
tumours.
The
aim
of
this
study
was
to
evaluate
the
usefulness
[68Ga]Ga-PSMA-11
for
preoperative
diagnosis
and
2-year
prognosis.
We
prospectively
screened
suspected
glioma
tumour.
qualitative
quantitative
results
were
compared
histopathological
examination.
glioblastoma
(GBM)
diagnostic
data
or
between
high-grade
(HGG)
low-grade
(LGG)
gliomas.
Overall
(OS)
progression
free
survival
(PFS)
analysed.
Forty-four
met
inclusion
criteria.
Twenty
them
had
positive
twenty-four
negative
scans.
sensitivity,
specificity,
predictive
value,
value
HGG
71.4
(95%
confidence
interval
–
51.3–86.8),
100.0
(79.4–100.0),
(83.1–100.0),
66.7
(44.7–84.4),
respectively.
For
differentiation
GBM
vs
non-GBM
best
parameter
tumor-to-background
ratio,
area
under
receiver
operating
characteristic
curve
0.81
(0.66–0.96;
42.2)
CI;
cut-off).
Patients
scans
similar
PFS
OS
HGG.
accumulation
negatively
affected
diagnosed
GBM.
showed
optimistic
may
be
prognostic
a
factor.
Registration
at
www.clinicaltrials.gov
09/06/2023
number
NCT05896449
Diagnostics,
Journal Year:
2023,
Volume and Issue:
13(3), P. 564 - 564
Published: Feb. 3, 2023
Background:
Recently,
several
studies
introduced
the
potential
use
of
positron
emission
tomography/computed
tomography
(PET/CT)
with
prostate-specific
membrane
antigen
(PSMA)-targeting
radiopharmaceuticals
in
radioiodine-refractory
thyroid
cancer
(TC).
Methods:
The
authors
accomplished
a
comprehensive
literature
search
original
articles
concerning
performance
PSMA-targeted
PET/CT
TC
patients.
Original
papers
exploring
this
molecular
imaging
examination
patients
undergoing
restaging
their
disease
were
included.
Results:
A
total
6
documents
diagnostic
(49
patients)
included
systematic
review.
reported
heterogeneous
values
detection
rates
TC,
ranging
from
25%
to
100%
and
overall
inferior
[18F]-fluorodeoxyglucose
when
two
examinations
compared.
Two
administration
[177Lu]PSMA-radioligands
theragnostic
purpose
three
Conclusions:
available
data
setting
are
limited
heterogeneous.
employment
PET
PSMA-targeting
did
not
affect
patient
management.
Nevertheless,
prospective
multicentric
needed
properly
assess
its
role
ACS Applied Nano Materials,
Journal Year:
2024,
Volume and Issue:
7(6), P. 5729 - 5744
Published: March 4, 2024
The
rapidly
advancing
field
of
nanomedicine
has
witnessed
the
emergence
polyurethane
nanoparticles
(PUNPs)
as
exceptionally
versatile
tools
with
transformative
potential.
This
comprehensive
review
dives
into
various
roles
that
PUNPs
play
in
realm
nanomedicine,
positioning
them
pivotal
components
therapeutic,
diagnostic,
and
theranostic
applications.
With
a
focus
on
their
unique
characteristics,
these
offer
platform
for
precision
at
nanoscale,
critical
attribute
intricate
landscape
medical
interventions.
precisely
navigates
through
biobased
synthesis
method
recent
applications
(2019–2023)
fields.
Furthermore,
it
explores
innovative
approaches
surface
functionalization,
elucidating
how
tailored
modifications
can
optimize
interaction
biological
entities.
Beyond
conventional
realm,
emerge
carriers
therapeutic
cargo
strategic
players
diagnostics
theranostics,
showcasing
multifaceted
utility.
In
conclusion,
this
beyond
generalized
statements,
offering
exploration
specific
attributes
make
indispensable
frontiers
nanomedicine.
Through
meticulous
examination
synthesis,
applications,
aims
to
contribute
different
understanding
PUNPs'
drug
delivery
systems,
imaging,
theranostics.
Journal of Clinical Medicine,
Journal Year:
2023,
Volume and Issue:
12(22), P. 7130 - 7130
Published: Nov. 16, 2023
Background:
prostate-specific
membrane
antigen
(PSMA)
ligand
PET
has
been
recently
incorporated
into
international
guidelines
for
several
different
indications
in
prostate
cancer
(PCa)
patients.
However,
there
are
still
some
open
questions
regarding
the
role
of
PSMA
castration-resistant
(CRPC).
The
aim
this
work
is
to
assess
clinical
value
PET/CT
patients
with
CRPC.
Results:
demonstrated
higher
detection
rates
comparison
conventional
imaging
and
allows
a
significant
reduction
number
M0
CRPC
its
real
impact
on
patients’
prognosis
an
question.
Moreover,
patients,
presents
sensitivity
specificity
limitations.
Due
heterogeneity,
may
present
mosaic
neoplastic
clones,
which
could
be
PSMA−/FDG+,
or
vice
versa.
Likewise,
unspecific
bone
uptake
(UBU)
second
primary
neoplasms
(SNPs)
overexpressing
neoangiogenic
vessels
represent
potential
issues.
Integrated
multi-tracer
(PSMA
[18F]FDG
PET)
together
multidisciplinary
discussion
allow
reaching
most
accurate
evaluation
each
patient
from
precision
medicine
point
view.
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: Jan. 2, 2025
PET/CT
targeting
prostate-specific
membrane
antigen
(PSMA)
is
commonly
used
in
patients
with
prostate
cancer.
PSMA
has
been
found
other
solid
tumours,
including
primary
brain
tumours.
The
aim
of
this
study
was
to
evaluate
the
usefulness
[68Ga]Ga-PSMA-11
for
preoperative
diagnosis
and
2-year
prognosis.
We
prospectively
screened
suspected
glioma
tumour.
qualitative
quantitative
results
were
compared
histopathological
examination.
glioblastoma
(GBM)
diagnostic
data
or
between
high-grade
(HGG)
low-grade
(LGG)
gliomas.
Overall
(OS)
progression
free
survival
(PFS)
analysed.
Forty-four
met
inclusion
criteria.
Twenty
them
had
positive
twenty-four
negative
scans.
sensitivity,
specificity,
predictive
value,
value
HGG
71.4
(95%
confidence
interval
–
51.3–86.8),
100.0
(79.4–100.0),
(83.1–100.0),
66.7
(44.7–84.4),
respectively.
For
differentiation
GBM
vs
non-GBM
best
parameter
tumour-to-background
ratio,
area
under
receiver
operating
characteristic
curve
0.81
(0.66–0.96;
42.2)
CI;
cut-off).
Patients
scans
similar
PFS
OS
HGG.
accumulation
negatively
affected
diagnosed
GBM.
showed
optimistic
may
be
prognostic
a
factor.
Registration
at
www.clinicaltrials.gov
09/06/2023
number
NCT05896449.
Information,
Journal Year:
2025,
Volume and Issue:
16(1), P. 58 - 58
Published: Jan. 16, 2025
Background:
Some
evidence
of
the
value
18F-fluorodesoxyglucose
([18F]FDG)
positron
emission
tomography
(PET)
imaging
for
assessment
gliomas
and
glioblastomas
(GBMs)
is
emerging.
The
aim
this
systematic
review
was
to
assess
role
[18F]FDG
PET-based
radiomics
machine
learning
(ML)
in
evaluation
these
neoplasms.
Methods:
A
wide
literature
search
PubMed/MEDLINE,
Scopus,
Cochrane
Library
databases
made
find
relevant
published
articles
on
ML
GBMs.
Results:
Eight
studies
were
included
review.
Signatures,
including
analysis
ML,
generally
demonstrated
a
possible
diagnostic
different
characteristics
GBMs,
such
as
methylation
status
O6-methylguanine-DNA
methyltransferase
(MGMT)
promoter,
isocitrate
dehydrogenase
(IDH)
genotype,
alpha
thalassemia/mental
retardation
X-linked
(ATRX)
mutation
status,
proliferative
activity,
differential
diagnosis
with
solitary
brain
metastases
or
primary
central
nervous
system
lymphoma,
prognosis
patients.
Conclusion:
Despite
some
intrinsic
limitations
affecting
review,
initial
insights
promising
technologies
GBMs
are
Validation
preliminary
findings
multicentric
needed
translate
approaches
clinical
setting.
Oxidative Medicine and Cellular Longevity,
Journal Year:
2022,
Volume and Issue:
2022, P. 1 - 11
Published: Oct. 11, 2022
The
most
prevalent
primary
malignant
tumor
of
CNS
is
glioma,
which
has
a
dismal
prognosis.
theory
oxidative
stress
one
the
important
theories
in
study
its
occurrence
and
development
mechanism.
In
this
study,
impacts
PCBP2
on
glioma
sufferers
possible
mechanisms
were
examined.
Patients
with
obtained
from
May
2017
to
July
2018.
Quantitative
PCR,
microarray
analysis,
western
blot
immunofluorescence
used
experiment.
mRNA
expression
level
protein
patients
upregulated
compared
paracancerous
tissue.
OS
DFS
low
higher
than
those
high
expression.
promoted
progression
metastasis
glioma.
reduced
stress-induced
apoptosis
suppressed
cGAS/STING
pathway
interlinked
cGAS
was
target
for
PCBP2.
METTL3-mediated
m6A
modification
increases
stability.
Along
cGAS-STING
signal
pathway,
decreased
that
caused,
might
be
potential
suppress
Clinical Nuclear Medicine,
Journal Year:
2023,
Volume and Issue:
48(8), P. 657 - 666
Published: June 3, 2023
Purpose
of
the
Report
Using
morphological
and
functional
imaging
to
discriminate
recurrence
from
postradiation-related
modifications
in
patients
with
glioblastomas
remains
challenging.
This
pilot
study
aimed
assess
feasibility
using
68
Ga–prostate-specific
membrane
antigen
(PSMA)
11
PET/CT
compared
18
F-FDOPA
detect
early
recurrence.
Methods
Nine
followed
up
for
who
received
MRI
during
12
months
follow-up
were
referred
both
Ga-PSMA-11
PET/CT.
The
SUV
max
,
lesion-to-striatum
ratio,
lesion-to-normal
parenchyma
lesion-to-salivary
gland
ratio
calculated.
Results
Good
correlation
between
Ga-PSMA
findings
was
seen
5
patients.
In
4
patients,
examinations
consistent
but
better
visualized
PSMA
Examinations
fifth
patient
suggestive
changes
analyzed
PET/CT,
which
displayed
relatively
low
uptake
DOPA
Conversely,
showed
conflicting
results:
not
detected
on
because
previously
introduced
bevacizumab
treatment;
another
patient,
recurrence,
there
an
mismatch
at
suspected
lesion
sites,
2
presented
inconsistent
findings.
Conclusions
Despite
a
few
discrepancies,
this
highlights
potential
role
discriminating
postradiation
inflammation
has
excellent
lesion-to-background
false-positive
false-negative
results
could
be
minimized
through
implementing
certain
protocols
before
performing
examination.
More
powerful
prospective
studies
are
required
validate
our
results.
Diagnostics,
Journal Year:
2023,
Volume and Issue:
13(24), P. 3610 - 3610
Published: Dec. 6, 2023
Background:
18F-Fluciclovine
([18F]FACBC)
has
been
recently
proposed
as
a
synthetic
radiolabeled
amino
acid
for
positron
emission
tomography
(PET)
imaging
in
patients
with
brain
neoplasms.
Our
aim
is
to
evaluate
the
diagnostic
performance
of
[18F]FACBC
PET
high-grade
glioma
(HGG)
patients,
taking
into
account
literature
data.
Methods:
A
comprehensive
search
was
performed.
We
included
original
articles
evaluating
detection
HGG
before
therapy
and
suspicion
tumor
recurrence.
Pooled
sensitivity,
specificity,
positive
negative
likelihood
ratios
(LR+
LR−),
odds
(DOR),
including
95%
confidence
intervals
(95%
CI),
were
measured.
Statistical
heterogeneity
publication
bias
also
assessed.
Results:
ten
studies
review
eight
meta-analysis
(113
patients).
Regarding
identification
HGG,
sensitivity
ranged
between
85.7%
100%,
pooled
estimate
92.9%
CI:
84.4–96.9%),
while
specificity
from
50%
70.7%
47.5–86.5%).
The
LR+,
LR−,
DOR
2.5,
0.14,
37,
respectively.
No
significant
statistical
or
found.
Conclusions:
evidence-based
data
demonstrate
good
accuracy
detection.
Due
still
limited
data,
further
are
warranted
confirm
promising
role
this
context.
